Phase II Clinical Study of Interferon+Sorafenib Combination Therapy in Advanced Renal Cell Carcinoma

Phase 2

• Conditions: Advanced renal cell carcinoma

• Registration Number: JPRN-UMIN000004067
• Lead Sponsor: Hokuriku Advanced Renal cell carcinoma Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-09-01
• Study Completion: 2015-07-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

1.Patinets being treated with Shosaikoto 2.Patients with autoimmunehepatitis 3.Known hypersensitivity to interferon or Sorafenib 4.Known hypersensitivity to biologics, such as vaccines 5.Myocardial infarction within the previous 12 months 6.Severe arrhythmias 7.Active or symptomatic angina pectoris or coronary artery disease 8.Poorly controlled hypertension 9.Previous history of renal failure 10.Poorly controlled diabetes mellitus 11.Active acute or chronic infection or serious intercurrent illness 12.Liver cirrhosis 13.Intracranial metastasis 14.Interstitial pulmonary disease 15.Severe mental disorder, such as severe depression 16.Pregnant, or women who have a possibility of pregnancy 17.Investigator determines as unsuitable

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Objective response

Secondary Outcome Measures

Name	Time	Method
Safety